Ten Years of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Evolution of Classification and Correlation with Follow-up in 50 Patients

被引：0
|
作者：
Grillo, F. [1 ]
Albertelli, M. [1 ]
Giannone, A. [1 ]
Mastracci, L. [1 ]
Annunziata, F. [1 ]
Arvigo, M. [1 ]
Minuto, F. [1 ]
Fiocca, R. [1 ]
Ferone, D. [1 ]
机构：
[1] Univ Genoa, Genoa, Italy
来源：
NEUROENDOCRINOLOGY | 2012年 / 96卷
关键词：
neuroendocrine; grade; prognosis;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [41] Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 11 - 12
  • [42] Health resource utilization among patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated at a tertiary referral center.
    Meng, Jie
    Jalbert, Jessica J.
    Casciano, Roman
    Brais, Lauren K.
    Ray, David
    Pulgar, Sonia J.
    Kulke, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Institutional initial experience in establishing Lu-177 Lutathera program for gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Wojtylak, Patrick
    Kardan, Arash
    Avril, Norbert
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [44] Hegemony and cost-effectiveness of endoscopic ultrasound (EUS) in the field of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs)
    De Angelis, C.
    Manfre, S. F.
    Bruno, M.
    Pellicano, R.
    MINERVA MEDICA, 2014, 105 (05) : 363 - 370
  • [45] SOMATOSTATIN RECEPTOR (SSTR) EXPRESSION AND PROLIFERATIVE INDEX (KI 67) IN 100 PATIENTS (PTS) WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS). CLINICAL-PATHOLOGICAL CORRELATION
    Oconnor, J. M.
    Belli, S.
    Pesce, V.
    Bestani, C.
    Mendez, G.
    Dominichini, E.
    Cabanne, A.
    Lopez, G.
    Marmissolle, F.
    Roca, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 379 - 380
  • [46] Is proliferative index (Ki-67) useful to stratify patients (pts) with G2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)? Clinicopathologic correlation.
    Angel, Martin
    Connor, Juan O.
    Pesce, Veronica
    Ariel Mendez, Guillermo
    Bestani, Claudia
    Marmissolle, Fabiana
    Giacomi, Nora
    Belli, Susana
    Domenichini, Enzo
    Chacon, Matias
    Zamora, Victor
    Maria Cabanne, Ana
    Parma, Patricia
    Luis Roca, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [47] Can tumor absorbed dose predict response to Peptide Receptor Radionuclide Therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?
    Mileva, M.
    Marin, G.
    Levillain, H.
    van Bogaert, C.
    Critchi, G.
    Marin, C.
    Flamen, P.
    Karfis, I
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 153 - 153
  • [48] The additive value of F-18 fluorodeoxyglucose PET imaging in grade 1 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Liotsou, T.
    Metaxas, M.
    Georgakopoulos, A.
    Tsoli, M.
    Panagaki, M.
    Kallergi, M.
    Alevroudis, E.
    Kaltsas, G.
    Chatziioannou, S.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 196 - 196
  • [49] Evaluation of the Concordance between the Stage of the Disease and Ki-67 Proliferation Index in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Ozaslan, E.
    Demir, S.
    Karaca, H.
    Guven, K.
    NEUROENDOCRINOLOGY, 2016, 103 : 27 - 27
  • [50] Trends in Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in India: A Report of Multicentre Data from a Web Based Registry
    Desai, G.
    Pande, P.
    Mansukhani, V
    Shah, R.
    Bhaduri, D.
    Sirohi, B.
    Shrikhande, S.
    Dhar, P.
    Sastry, R.
    Sikora, S.
    Palepu, J.
    NEUROENDOCRINOLOGY, 2018, 106 : 70 - 70
12345